Journal of Medicinal Chemistry · 2017 · 34 citations · 46 references
MedicineMedicinal ChemistryPharmacologyDrug DiscoveryInflammationPharmacodynamicsAnalgesic PharmacologyAnti-inflammatory PharmacologyInflammation PharmacologyInflammatory ArthritisAnti-inflammatory ActivityAnti-inflammatory Drug DiscoveryAnti-inflammatory TherapeuticsCyclooxygenase InhibitorsMurine ModelsPharmacodynamic MechanismsPharmacodynamics Of AnalgesicsSelective Cyclooxygenase-2 Inhibitors
In this report, we disclose the design and synthesis of a series of pentafluorosulfanyl (SF 5 ) benzopyran derivatives as novel COX-2 inhibitors with improved pharmacokinetic and pharmacodynamic properties. The pentafluorosulfanyl compounds showed both potency and selectivity for COX-2 and demonstrated efficacy in several murine models of inflammation and pain. More interestingly, one of the compounds, R, S - 3a, revealed exceptional efficacy in the adjuvant induced arthritis (AIA) model, achieving an ED 50 as low as 0.094 mg/kg. In addition, the pharmacokinetics of compound R, S - 3a in rat revealed a half-life in excess of 12 h and plasma drug concentrations well above its IC 90 for up to 40 h. When R, S - 3a was dosed just two times a week in the AIA model, efficacy was still maintained. Overall, drug R, S - 3a and other analogues are suitable candidates that merit further investigation for the treatment of inflammation and pain as well as other diseases where COX-2 and PGE 2 play a role in their etiology.
46
A new and sensitive method for measuring thermal nociception in cutaneous hyperalgesia
Kenneth Hargreaves, Ronald Dubner, Frederick J. Brown et al. · Pain · 1988 · 5.2K citations